CRBU vs. PSTX, FHTX, SOPH, GLUE, CLLS, AUTL, IMTX, MESO, RLAY, and HUMA
Should you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Poseida Therapeutics (PSTX), Foghorn Therapeutics (FHTX), SOPHiA GENETICS (SOPH), Monte Rosa Therapeutics (GLUE), Cellectis (CLLS), Autolus Therapeutics (AUTL), Immatics (IMTX), Mesoblast (MESO), Relay Therapeutics (RLAY), and Humacyte (HUMA). These companies are all part of the "medical" sector.
Poseida Therapeutics (NASDAQ:PSTX) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk.
46.9% of Poseida Therapeutics shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 2.9% of Poseida Therapeutics shares are owned by insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Poseida Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.56, meaning that its stock price is 156% more volatile than the S&P 500.
In the previous week, Poseida Therapeutics had 11 more articles in the media than Caribou Biosciences. MarketBeat recorded 14 mentions for Poseida Therapeutics and 3 mentions for Caribou Biosciences. Poseida Therapeutics' average media sentiment score of 1.40 beat Caribou Biosciences' score of 1.08 indicating that Caribou Biosciences is being referred to more favorably in the news media.
Poseida Therapeutics received 17 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 65.38% of users gave Poseida Therapeutics an outperform vote while only 53.13% of users gave Caribou Biosciences an outperform vote.
Poseida Therapeutics presently has a consensus target price of $14.67, indicating a potential upside of 423.81%. Caribou Biosciences has a consensus target price of $21.50, indicating a potential upside of 667.86%. Given Poseida Therapeutics' higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Poseida Therapeutics.
Caribou Biosciences has lower revenue, but higher earnings than Poseida Therapeutics. Poseida Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Poseida Therapeutics has a net margin of -131.95% compared to Poseida Therapeutics' net margin of -345.05%. Poseida Therapeutics' return on equity of -33.42% beat Caribou Biosciences' return on equity.
Summary
Caribou Biosciences beats Poseida Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Caribou Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Caribou Biosciences Competitors List
Related Companies and Tools
